Steven K. Galson - 11 Jun 2026 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Reporting relationship: Director
Issuer ticker: BCRX
Reported as of: 11 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Jun 2026, 16:30:38 UTC
Prior SEC filing: 16 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Alane P. Barnes, by power of attorney

Key filing fact

Steven K. Galson filed Form 4 for BIOCRYST PHARMACEUTICALS INC (BCRX) on 15 Jun 2026.

Key facts

This page summarizes Steven K. Galson's Form 4 filing for BIOCRYST PHARMACEUTICALS INC (BCRX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 15 Jun 2026, 16:30.

Change

Previous filing in this sequence was filed on 16 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001495328 Primary reporting owner

Galson Steven K

Relationship: Director
Address: 4505 EMPEROR BLVD., SUITE 200, DURHAM
Signature: /s/ Alane P. Barnes, by power of attorney
Signature date: 15 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BCRX transaction

Common Stock

Award

Transaction value
Shares: +15,294
Change %: +122%
Price: $0.000000^*
Shares after: 27,794
Date: 11 Jun 2026
Ownership: Direct
Footnotes: F1

BCRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 58,371
Date: 11 Jun 2026
Ownership: By Trust
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BCRX transaction Derivative

Automatic Stock Option Grant

Award

Transaction value
Shares: +33,540
Change %
Price: $0.000000^*
Shares after: 33,540
Date: 11 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 33,540
Exercise price: $8.50
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.

Footnote F2

On July 23, 2025, the Reporting Person transferred 12,491 shares to a living trust for no consideration. The Reporting Person is an indirect beneficial owner of the shares held by the trust.

Footnote F3

Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.